Field Study on Cefquinome in Treatment of Clinical Bovine Mastitis

Document Type : Original Article

Authors

1 Pharmacology, Veterinary Medicine, Animal Health Research Institute, Tanta lab., Cairo, Egypt

2 Department of Food Hygiene, Animal Health Research Institute (AHRI), Tanta Branch, Agricultural Research Center (ARC), Egypt

3 Department of Pharmacology, Animal Health Research Institute (AHRI), Tanta Branch, Agricultural Research Center (ARC), Egypt

4 Department of Biochemistry and Feed Deficiency, Animal Health Research Institute (AHRI), Tanta Branch, Agricultural Research Center (ARC), Egypt

Abstract

The current study aims to identify the main pathogens responsible for mastitis, and to investigate the effect of extended treatment of both cefquinome and cefquinome-diphenhydramine combination in treatment of mastitis in cows, with evaluation of its residues in milk after treatment. Besides, serum biochemical analysis including AST, ALT, creatinine, urea, IgE, histamine, in addition to antioxidant status )GSH and MDA( were also assessed. The study used 20 native mixed breed dairy cows which were categorized into four groups made up of five cows in each group; (G1): clinically healthy and negative to California test (CMT) as a negative control group, (G2): mastitic +ve CMT as a positive control group, (G3): mastitic +ve CMT and given therapeutic dose of Cefquinome alone, (G4): mastitic +ve CMT and treated with therapeutic doses of Cefquinome and diphenhydramine. The obtained results revealed that coagulase negative Staphylococcus aureus, coagulase positive Staphylococcus aureus, Streptococcus agalactia and E. coli were isolated from clinically mastitic cases. In residue depletion study, Cefquinome remained detectable in treated cows` milk until the 10th day of treatment (0.006±0.002µg/ml), although it was below the Maximum Residual Limit (20 µg/kg). In pharmacodynamic study, cefquinome–diphenhydramine treatment resulted in significant attenuation of mastitis-associated increases in serum MDA, IgE, and histamine concentrations, while maintaining normal hepatic function parameters, as evidenced by unaltered serum AST and ALT activities. It could be concluded that cefquinome–diphenhydramine treatment exhibits superior therapeutic efficacy over cefquinome monotherapy in bovine mastitis, as demonstrated by enhanced modulation of inflammatory markers and improved antioxidant status. 

Keywords

Main Subjects



Articles in Press, Corrected Proof
Available Online from 29 January 2025
  • Receive Date: 11 November 2024
  • Revise Date: 26 January 2025
  • Accept Date: 26 January 2025